遺伝子変異が原因の血管の病気に対する、より精密な医療について
Precision Medicine for Somatic Mutation-Driven Vascular Anomalies
- 血管の病気の多くは、体の成長の途中で起きた遺伝子の変化(体細胞変異)が原因で起こります。
- この変化によって、特定の信号が常にオンになり、血管が異常に増えたり形が変わったりします。
- 最近では、この遺伝子の変化を特定し、それに合わせた薬(標的薬)で治療する「精密医療」が進んでいます。
Vascular anomalies, including proliferative vascular tumours and structural malformations, are largely driven by postzygotic somatic mutations that constitutively activate key signalling pathways, mainly the PI3K/AKT/mTOR and RAS/MAPK pathways. This molecular understanding has shifted clinical management from empiric interventions towards precision medicine. In this review, the interactions between somatic mosaicism, germline predispositions (e.g., PTEN hamartoma tumour syndrome), and microenvironmental risk factors in the context of lesional progression are described. We synthesized data on genotype‒phenotype correlations-such as PIK3CA mutations in lymphatic and venous malformations, KRAS/MAP2K1 mutations in arteriovenous malformations, and cerebral cavernous malformation (CCM) complex dysfunctions in cerebral cavernous anomalies-while fundamentally differentiating the mechanistic dependencies of true malformations from those of proliferative tumours. Targeted therapies, including mTOR, PI3Kα, and MEK inhibitors, have exhibited significant clinical efficacy in the treatment of pathway-specific anomalies. Despite these advances, therapeutic resistance and drug dependency persist. Future directions include the development of integrated diagnostic frameworks combining tissue biopsies with longitudinal cell-free DNA (cfDNA) monitoring, optimizing dual-pathway combination strategies, and advancing cellular models to reshape the management of vascular anomalies.
この論文で紹介されている治療法は、まだ新しいものが多く、すべての人に有効とは限りません。また、治療法によっては副作用や効果が出にくい場合もあります。治療については、必ず主治医にご相談ください。
- Journal
- The British journal of dermatology(2026 Sep)
- Authors
- 4名
- Type
- Journal Article